Prognostic value of bone marrow angiogenesis in patients with multiple myeloma undergoing high-dose therapy

Bone Marrow Transplantation

Volumn 34, Issue 3, 2004, Pages 235-239

  Kumar, S ^a   Gertz, M A ^a   Dispenzieri, A ^a   Lacy, M Q ^a   Wellik, L A ^a   Fonseca, R ^a   Lust, J A ^a   Witzig, T E ^a   Kyle, R A ^a   Greipp, P R ^a   Rajkumar, S Vincent ^a  

^a MAYO CLINIC   (United States)

Author keywords

Angiogenesis; Multiple myeloma; Prognosis; Refractory; Stem cell transplantation

Indexed keywords

CD34 ANTIGEN; CYCLOPHOSPHAMIDE; DEXAMETHASONE; DOXORUBICIN; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MELPHALAN; THALIDOMIDE; VINCRISTINE;

ADULT; AGED; ANGIOGENESIS; ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; BONE MARROW; CANCER PATIENT; CANCER SURVIVAL; CONTROLLED STUDY; DENSITY; DRUG MEGADOSE; FEMALE; GRAFT VERSUS HOST REACTION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; MALE; MICROVASCULATURE; MULTIPLE MYELOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TIME; TREATMENT OUTCOME; WHOLE BODY RADIATION;

ADULT; AGED; ANTIGENS, CD34; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BIOPSY; BONE MARROW; DISEASE-FREE SURVIVAL; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICROCIRCULATION; MIDDLE AGED; MULTIPLE MYELOMA; NEOVASCULARIZATION, PATHOLOGIC; PROGNOSIS; SURVIVAL ANALYSIS; TIME FACTORS;

EID: 4344640371     PISSN: 02683369     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bmt.1704555     Document Type: Article

References (33)

1. Bataille R, Harousseau JL. Multiple myeloma. N Engl J Med 1997; 336: 1657-1664.
2. Kyle RA, Gertz MA, Witzig TE et al. Review of 1027 patients with newly diagnosed multiple myeloma. Mayo Clin Proc 2003; 78: 21-33.
3. Jemal A, Murray T, Samuels A et al. Cancer statistics, 2003. CA Cancer J Clin 2003; 53: 5-26.
4. Child JA, Morgan GJ, Davies FE et al. High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma. N Engl J Med 2003; 348: 1875-1883.
5. Attal M, Harousseau JL, Stoppa AM et al. A prospective, randomized trial of autologous bone marrow transplantation and chemotherapy in multiple myeloma. Intergroupe Francais du Myelome. N Engl J Med 1996; 335: 91-97.
6. Folkman J. Seminars in medicine of the Beth Israel Hospital, Boston. Clinical applications of research on angiogenesis. N Engl J Med 1995; 333: 1757-1763.
7. Folkman J. New perspectives in clinical oncology from angiogenesis research. Eur J Cancer 1996; 32A: 2534-2539.
8. Rajkumar SV, Leong T, Roche PC et al. Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res 2000; 6: 3111-3116.
9. Rajkumar SV, Greipp PR. Prognostic factors in multiple myeloma. Hematol Oncol Clin North Am 1999; 13: 1295-1314 xi.
10. Vacca A, Ribatti D, Roncali L et al. Bone marrow angiogenesis and progression in multiple myeloma. Br J Haematol 1994; 87: 503-508.
11. Sezer O, Niemoller K, Eucker J et al. Bone marrow microvessel density is a prognostic factor for survival in patients with multiple myeloma. Ann Hematol 2000; 79: 574-577.
12. Aguayo A, Kantarjian H, Manshouri T et al. Angiogenesis in acute and chronic leukemias and myelodysplastic syndromes. Blood 2000; 96: 2240-2245.
13. Hussong JW, Rodgers GM, Shami PJ. Evidence of increased angiogenesis in patients with acute myeloid leukemia. Blood 2000; 95: 309-313.
14. Schneider P, Jerome MV, Paysant J et al. The role of angiogenesis in leukemia proliferation. Am J Pathol 1999; 155: 1007-1008.
15. Perez-Atayde AR, Sallan SE, Tedrow U et al. Spectrum of tumor angiogenesis in the bone marrow of children with acute lymphoblastic leukemia. Am J Pathol 1997; 150: 815-821.
16. Kini AR, Kay NE, Peterson LC. Increased bone marrow angiogenesis in B cell chronic lymphocytic leukemia. Leukemia 2000; 14: 1414-1418.
17. Rajkumar SV, Greipp PR. Angiogenesis in multiple myeloma. Br J Haematol 2001; 113:-565.
18. Rajkumar SV, Mesa RA, Fonseca R et al. Bone marrow angiogenesis in 400 patients with monoclonal gammopathy of undetermined significance, multiple myeloma, and primary amyloidosis. Clin Cancer Res 2002; 8: 2210-2216.
19. Kumar S, Fonseca R, Dispenzieri A et al. Bone marrow angiogenesis in multiple myeloma: effect of therapy. Br J Haematol 2002; 119: 665-671.
20. Rajkumar SV, Fonseca R, Witzig TE et al. Bone marrow angiogenesis in patients achieving complete response after stem cell transplantation for multiple myeloma. Leukemia 1999; 13: 469-472.
21. Munshi NC, Wilson C. Increased bone marrow microvessel density in newly diagnosed multiple myeloma carries a poor prognosis. Semin Oncol 2001; 28: 565-569.
22. Kaplan E, Meier P. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 53: 457-481.
23. Ahn MJ, Park CK, Choi JH et al. Clinical significance of microvessel density in multiple myeloma patients. J Korean Med Sci 2001; 16: 45-50.
24. Vacca A, Ribatti D, Roccaro AM et al. Bone marrow angiogenesis in patients with active multiple myeloma. Semin Oncol 2001; 28: 543-550.
25. Kumar S, Fonseca R, Dispenzieri A et al. Prognostic value of angiogenesis in solitary bone plasmacytoma. Blood 2003; 101: 1715-1717.
26. Bellamy WT, Richter L, Frutiger Y, Grogan TM. Expression of vascular endothelial growth factor and its receptors in hematopoietic malignancies. Cancer Res 1999; 59: 728-733.
27. Rajkumar SV, Yoon S, Li C et al. Angiogenesis in myeloma: expression of basic fibroblast growth factor (bFGF), vascular endothelial growth factor (VEGF) and their receptors by neoplastic plasma cells. Blood 1999; 94: 303b.
28. Di Raimondo F, Azzaro MP, Palumbo G et al. Angiogenic factors in multiple myeloma: higher levels in bone marrow than in peripheral blood. Haematologica 2000; 85: 800-805.
29. Vacca A, Ria R, Ribatti D et al. A paracrine loop in the vascular endothelial growth factor pathway triggers tumor angiogenesis and growth in multiple myeloma. Haematologica 2003; 88: 176-185.
30. Alexandrakis G, Passam H, Boula A et al. Relationship between circulating serum soluble interleukin-6 receptor and the angiogenic cytokines basic fibroblast growth factor and vascular endothelial growth factor in multiple myeloma. Ann Hematol 2003; 82: 19-23.
31. Tai YT, Podar K, Gupta D et al. CD40 activation induces p53-dependent vascular endothelial growth factor secretion in human multiple myeloma cells. Blood 2002; 99: 1419-1427.
32. Dankbar B, Padro T, Leo R et al. Vascular endothelial growth factor and interleukin-6 in paracrine tumor-stromal cell interactions in multiple myeloma. Blood 2000; 95: 2630-2636.
33. Xu JL, Lai R, Kinoshita T et al. Proliferation, apoptosis, and intratumoral vascularity in multiple myeloma: correlation with the clinical stage and cytological grade. J Clin Pathol 2002; 55: 530-534.